drugset / Trial / NCT03243656

Eltrombopag & Cyclosporine in Children With Sever Aplastic Anemia

NCT03243656

Phase 4 Completed 20 enrolled Assiut University
RandomizedParallel-groupOpen-labelTreatment

Summary

Aplastic anemia is a rare disorder characterized by pancytopenia and a hypo cellular bone marrow.but,It is very serious disease causing morbidity and mortality. Aplastic anemia can be treated effectively with haematopoietic stem cell transplantation and immunosuppressive drug regimens but haematopoietic stem cell transplantation has limitations due to its cost and many patient are unsuitable. Immunosuppressive drug has a significant number of patients have persistent cytopenias. Currently, the treatment of these patients is regular transfusion, which are expensive, inconvenient, and associated with serious side effects related to iron overload and transfusion. Eltrombopag is an oral thrombopoietin mimetic that selectively binds at the transmembrane and juxtamembrane domains of the thrombopoietin receptor, at sites distinct from the binding site of thrombopoietin therefore it does not compete for binding with the native molecule. It promoting thrombopoiesis and release of platelets from mature megakaryocytes. Also, promote other hematopoietic stem cell as well as in thrombopoiesis .

Timeline

Start
2017-12-20
Primary completion
2019-12-29
Completion
2020-01-05

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Eltrombopag Small molecule Oral

Indications

No indication recorded.